TWT-202

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
72 patients (estimated)
Sponsors
Treadwell Therapeutics, Inc
Tags
Antimetabolites, Chemotherapy, Hypomethylating Agents (HMA), PLK4 Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1566
NCT Identifier
NCT04730258

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.